Objective To research the genetic susceptibility of proliferative diabetic retinopathy (PDR) in Han patients with type 2 diabetes from Southern China.Methods A cross-sectional study was performed under the informed consent of the patients.Patients with type 2 diabetes in the Dongguan Eye Study from September 2011 to February 2012 and relative patients treated in Guangdong General Hospital from July 2017 to March 2018 were included in this study,including 100 patients with diabetes mellitus(DM) and 120 patients with PDR.Whole exome sequencing was used to identify DNA mutation in peripheral blood samples from 22 type 2 diabetic patients without retinopathy (DM group) and 23 diabetic patients with PDR (PDR group).Genotype and allele of the nine selected single-nucleotide polymorphisms (SNPs) were tested and analyzed by SnaPshot technology in another 78 DM patients without retinopathy and 97 PDR patients.Results A total of 75 SNPs were associated with PDR (P＜0.01),involving 53 genes.Eleven gene loci were in the exon region and 7 were non-synonymous mutations.Nine exon loci of 8 genes with significant differences were screened out for the verification.SnaPshot SNP genotyping technique found that there were no significant differences in allele and genotype frequency in the nine selected SNPs between PDR group and DM group (all at P＞0.05).However,7 haplotypes distribution frequencies were significantly different between PDR group and DM group (all at P＜0.01).Hapl and Hap4 might reduce the risk of PDR (both at OR＜1,P＜0.05),and Hap2 might increase the risk of PDR (OR＞ 1,P＜0.05).Conclusions The occurrence of PDR probably has a genetic susceptibility in type 2 DM patients of Han nationality in Southern China.

目的:分析血栓通联合递法明片治疗方案对于单纯性糖尿病视网膜病变患者视力、眼底及黄斑水肿的影响,探讨联合用药的作用机制及应用前景.方法:选取2015年3月至2017年2月收集的70例糖尿病视网膜病变患者临床资料,对照组给予口服维生素B1片、糖尿病基础治疗方案,实验组采用复方血栓通+递法明片治疗方案.两组在行电凝时检查视力、眼压、眼底荧光血管造影等情况,并对比治疗前后视力、眼底及视网膜黄斑水肿差异.结果:实验组视力恢复、黄斑厚度变化等指标改善效果显著优于对照组(P<0.05).实验组达到89.4%,高于对照组的74.2%,比较差异显著(P<0.05).结论:复方血栓通联合递法明片可辅助改善糖尿病视网膜病变患者视力、眼底病变及黄斑水肿效果,增强手术效果,具有一定的研究推广价值.

目的：比较拉坦前列素联合马来酸噻吗洛尔与单用拉坦噻吗滴眼液对高眼内压患者的降眼压效果、药物依从性和安全性。方法选取青光眼或高眼压症患者135例，随机分成两组，A组（ n＝67）接受拉坦前列素联合马来酸噻吗洛尔治疗，B组（ n＝68）单用拉坦噻吗滴眼液治疗。比较基线和第6个月时每天平均眼内压的变化。结果治疗前两组患者的眼内压水平相似，A组为（26．2±2．24）mmHg，B组为（26．9±2．5）mmHg（P＝0．53）；在第6个月时，A组眼内压水平为（16．3±1．6）mmHg，与基线值比较差异有统计学意义（P＜0．001），而B组患者眼内压水平为（16．1±1．3）mmHg，与基线值比较差异有统计学意义（P＜0．001），两组的治疗均可视为有效。两组第6个月的眼内压水平也相似，差异无统计学意义（P＝0．62）。 A组患者的药物依从性为48．2％，B组患者的药物依从性为64．3％。 A组和B组分别有76．1％和76．5％未报告出现不良事件。 A组和B组分别有9．0％和7．4％报告出现药物相关不良事件。结论使用拉坦前列素联合马来酸噻吗洛尔与单用拉坦噻吗滴眼液具有相似的疗效，而后者的药物依从性较高。

目的:观察六锐胶囊联合视网膜激光光凝治疗糖尿病视网膜病变的临床疗效.方法:将165例糖尿病视网膜病变患者随机分为单纯激光治疗组(激光组)、单纯药物治疗组(药物组)和激光联合药物治疗组(激光十药物组),激光组采用激光治疗,药物组采用口服六锐胶囊治疗,激光十药物组采用六锐胶囊联合视网膜激光光凝治疗.观察比较两组患者治疗前后视力、眼底出血和渗出及视网膜新生血管情况.结果:治疗后,各组患者在视力提高≥1行、眼底出血和渗出减少及视网膜新生血管阻止等方面改善情况较治疗前差异具有统计学意义(P＜0.05);与激光组比较,药物组患者在视力变化、眼底出血和渗出减少方面差异无统计学意义(P＞0.05),在视网膜新生血管阻止方面差异具有统计学意义(P＜0.05);激光组十药物组患者在视力变化、眼底出血和渗出减少及视网膜新生血管阻止等方面情况优于其他两组(P＜0.05).结论:六瑞胶囊联合视网膜激光治疗可显著改善糖尿病视网膜病变患者眼底出血、渗出等症状,降低新生血管发生率,且无不良反应,值得临床推广应用.